Menu
Search
|

Menu

Close
X

Cidara Therapeutics Inc CDTX.OQ (NASDAQ Stock Exchange Global Market)

3.78 USD
+0.10 (+2.72%)
As of 5:19 PM GMT
chart
Previous Close 3.68
Open 3.61
Volume 2,780
3m Avg Volume 20,917
Today’s High 3.80
Today’s Low 3.60
52 Week High 8.55
52 Week Low 3.37
Shares Outstanding (mil) 16.86
Market Capitalization (mil) 123.10
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.43 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-2.422
FY17
-3.202
FY16
-3.315
FY15
-2.343
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
2.01
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
16.05
15.71
LT Debt to Equity (MRQ)
vs sector
14.96
11.53
Return on Investment (TTM)
vs sector
-72.93
15.05
Return on Equity (TTM)
vs sector
-77.58
16.62

EXECUTIVE LEADERSHIP

Scott Rocklage
Chairman of the Board, Since 2013
Salary: --
Bonus: --
Jeffrey Stein
President, Chief Executive Officer, Principal Financial Officer, Director, Since 2018
Salary: $263,846.00
Bonus: $59,680.00
Brady Johnson
Principal Accounting Officer, Since 2018
Salary: --
Bonus: --
Kenneth Bartizal
Chief Development Officer, Since 2014
Salary: $213,937.00
Bonus: --
Paul Daruwala
Chief Commercial Officer, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

6310 Nancy Ridge Dr Ste 101
SAN DIEGO   CA   92121-3209

Phone: +1858.7526170

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. The Company is also developing CD201, its bispecific antimicrobial immunotherapy.

SPONSORED STORIES